Background
Data are limited on the extent of in utero transfer of dolutegravir (DTG) and efavirenz (EFV), two drugs widely used in pregnancy. To evaluate in utero exposure of these agents, we measured drug concentrations in hair among women living with HIV (WHIV) and their newborns in IMPAACT 2010.
Methods
643 WLHIV in 9 countries (predominantly Africa) were randomized at 14-28 weeks gestation to start DTG+emtricitabine(F)/tenofovir alafenamide(TAF), DTG+F/tenofovir disoproxil fumarate(TDF), or efavirenz (EFV)/F/TDF. Maternal and infant hair samples were collected shortly after delivery. DTG and EFV levels were analyzed using validated liquid chromatography/tandem mass spectrometry methods. The lower (LLOQ) and upper (ULOQ) limits of quantification were 0.02 and 20 ng/mg (hair) for DTG and 0.05 and 20 ng/mg for EFV, respectively. Weight-normalized drug levels in hair were log-transformed. Ratios of infant-to-maternal concentrations were calculated to assess transfer. Linear regression models were fit to assess associations between adverse perinatal outcomes and maternal hair drug concentrations, with each drug analyzed separately.
Results
We analyzed hair from a subset of 370 DTG-exposed and 163 EFV-exposed mother-infant pairs. Median maternal age was 26 years (IQR 22–31), gestational age at ART initiation 22 weeks (IQR 18–25), and gestational age at birth 40 weeks (IQR 39–41). Hair was collected at median 6 days postpartum (IQR 3–8). The median DTG concentration was 3.9 ng/mg (IQR 1.8–5.8) for mothers. Infant DTG concentrations were >ULOQ in 91% of samples; for those <ULOQ, the median concentration was 13.7 ng/mg (IQR 8.8–17.5). The infant-to-mother ratio of mean log10 DTG concentrations was 0.83 (95% CI 0.77 to 0.88) with no difference in ratios between DTG+FTC/TAF vs. DTG+FTC/TDF (0.79 vs. 0.87; p=0.181). The median concentration of EFV for mothers was 7.3 ng/mg (IQR 4.2–13.5) and 5.3 ng/mg (IQR 3.8–8.2) for infants, with only 3% >ULOQ. The infant-to-maternal ratio of mean log10 EFV concentrations was –0.14 (95% CI –0.19 to –0.09), representing approximately 90% lower mean transfer than for DTG transfer (p<0.001). Maternal DTG and EFV levels were not associated with preterm birth, small-for-gestational-age, or neonatal death (all p>0.05).
Conclusions
Our results suggest in utero DTG exposure was higher than EFV exposure based on hair concentrations, but the extent of drug exposure was not associated with adverse birth outcomes. Our findings support current recommendations for prenatal DTG use.